Düsseldorf, 4. Februar 2021 – Der innovative Medikamentenkandidat PRI-002 gegen Alzheimer-Demenz wird in weiteren klinischen Studien an Patienten getestet.
“The drug candidate PRI-002 realizes a completely new and highly innovative anti-prionic mechanism of action. It is able to break down the neurotoxic Abeta oligomers in the brain and convert them into harmless monomers,” explains Dieter Willbold, Professor of Physical Biology at Heinrich Heine University in Düsseldorf and Director of the Institute of Structural Biochemistry (IBI-7) at Forschungszentrum Jülich. He is also member of Priavoid’s Supervisory Board and founder of Priavoid. Other compounds in the Priavoid pipeline also exhibit this mechanism. All specifically designed active ingredients consist of D-enantiomeric amino acid building blocks. “Priavoid is using the anti-prionic mechanism of action with the D-peptide platform technology for drug development against additional neurodegenerative diseases,” continues Prof. Dr. Dr. h.c. Detlev Riesner, co-founder of the biotech companies Qiagen and Evotec and Chairman of the Supervisory Board of Priavoid. Professor Stanley Prusiner, University of California, San Francisco (UCSF) and 1997 Nobel Laureate for the prion research he founded, is delighted that the application of the concept of prions to Alzheimer’s disease is now expected to lead to a breakthrough in treatment. Professor Prusiner has been a member of Priavoid’s supervisory board since the beginning of December 2020. The D-enantiomeric active ingredients are very stable in the human body and can therefore be administered orally as tablets or capsules. “This is a very patient convenient route of administration especially for elder patients”, stated Dagmar Jürgens, Director of Clinical Research at Priavoid. “We will intensively pursue the development of our platform to provide patients with a treatment for neurodegenerative diseases as soon as possible” said Philipp Bürling, CEO of Priavoid.